Yarrow Bioscience Inc
YARWHealthcare|Biotechnology|US
$15.60
+2.00 (+14.71%)
DCF Value
$23.72
Tangible Book / Share
$25.71
Cash / Share
$26.72
About
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Stock Price
-11.7%(1Y)
1M
-21.5%
3M
-62.3%
6M
-52.8%
YTD
-46.2%
1Y
-14.0%
3Y
-90.8%
5Y
-98.7%
Pipeline Summary
1 total trials0
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Phase 2Recruiting
Enrollment: 232 participants
Key Facts
Market Cap$145.1M
Employees10 (-23% YoY)
CEORebecca Velez Frey
IPO DateJul 28, 2026
Beta2.13
52-Week Range$12.385 – $46.95
Avg Volume17,939
ExchangeNASDAQ
Websiteyarrowbioscience.com
Ownership
Float90.4%
Shares Outstanding9.3M
Recent Insider Trades
Payton LoriAWARD
Oct 29, 202699,827 shares @ $20.00
Alford RachaelAWARD
Oct 29, 202689,844 shares @ $20.00
Frey RebeccaAWARD
Oct 29, 2026465,857 shares @ $20.00
Ryder StevenAWARD
Oct 29, 2026113,137 shares @ $20.00
Zeronda TylerAWARD
Oct 29, 2026156,115 shares @ $20.00
Peers
Recent News
Buy, Sell, or Hold? Friday’s Top Upgrades and Downgrades: Becton Dickinson, BJ’s Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More
Nov 6, 2026 · 247wallst.com
Yarrow Bioscience Announces Participation in November Investor Events
Nov 2, 2026 · businesswire.com
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)
Sep 21, 2026 · defenseworld.net
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Sep 14, 2026 · businesswire.com
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Sep 10, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:41 AM